Endoxifen-d5

CAT: 0804-HY-18719ESSize: 1 mgDry Ice: NoHazardous: No
CAT#: HY-18719ESSize: 1 mg
Selected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Endoxifen-d5 is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].
CAS Number
[1185244-45-4]
UNSPSC
12352005
Hazard Statement
H302, H312, H332, H361, H413
Target
Cytochrome P450; Drug Metabolite; Estrogen Receptor/ERR; Parasite
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Field of Research
Cancer
Purity
97.52
Solubility
10 mM in DMSO
Smiles
[2H]C([2H])([2H])C([2H])([2H])/C(C1=CC=CC=C1)=C(C2=CC=C(C=C2)O)/C3=CC=C(C=C3)OCCNC
Molecular Formula
C25H22D5NO2
Molecular Weight
378.52
Precautions
H302, H312, H332, H361, H413
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Goetz MP, et al. Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor. Oncology (Williston Park) . 2009 Dec;23 (14) :1233-4, 1236.|[3]Wu X, et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 2009 Mar 1;69 (5) :1722-7.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
Aromatase/CYP19A1